Autolus drags on Arix after weak period for CAR-T player

Profits and loss document with calculator and pen
Autolus is one of several companies, including Arix, in Neil Woodford’s portfolio that have suffered stock price drops. (a-wrangler/iStock/Getty Images Plus)

The problems facing chimeric antigen receptor T-cell (CAR-T) startup Autolus Therapeutics have infected one of its key investors, Arix Bioscience. Arix reported a 15% drop in its net asset value (NAV) as a result of the fast-falling share price of the troubled British biotech, which recently delayed multiple cell therapy programs.

Autolus’ share price fell 51% over the course of the first half of Arix’s financial year, causing the NAV of the biotech invest to fall 15% to £231.8 million ($282.8 million). Arix’s stock price has fallen faster than its NAV, dropping 30% in three months. Despite the problems, some observers think Arix is well set to turn things around.  

“With ample cash, reducing opex and multiple catalysts, we see significant potential upside from internal and external technical factors,” analysts at Jefferies wrote in a note to investors.


Industry Insight Survey: Direct-to-Patient Distribution of Clinical Supplies

This industry survey seeks to gain insight on trial sponsors' perspective on offering a DTP option and their current level of awareness and understanding of any factors that may influence their ability to do so. The first 50 qualified respondents will receive a $5 Amazon gift card.

Arix’s portfolio of biotechs presents it with plenty of opportunities to improve its fortunes. Atox Bio is set to post phase 3 data in necrotising soft tissue infection by the end of the year, with a readout from an acute kidney infection trial to follow in the second half of 2020.

Harpoon Therapeutics, fueled by money from its IPO, is also heading toward a slate of readouts. Data from trials run by Imara, Pharmaxis and Verona Pharma are on the horizon, too.

However, Autolus, the most valuable asset in Arix’s portfolio, remains key to the prospects of the biotech investor. Autolus is set to share data from phase 1 trials of AUTO1 and AUTO3 data by the end of the year, but a delay to manufacturing site qualification and the decision to shift lanes in the face of tough competition in BCMA are holding back the wider portfolio.

Autolus is one of several companies, including Arix, in Neil Woodford’s portfolio that have suffered stock price drops in the wake of the fund manager’s decision to freeze trading in one of his investment vehicles. 

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

J&J and Ethicon reached a deal with the attorneys general of 41 states and DC, agreeing to pay nearly $117 million.